Is oesophageal perforation an emergency? Yes. An oesophageal perforation, also called esophageal rupture, is a hole through the wall of the food pipe. Escaped digestive contents can damage and infect nearby tissues. Boerhaave syndrome is a form associated with a pressure injury, often after forceful vomiting; procedure-related injuries are another important group. Cleveland Clinic: emergency anatomy; WSES: injury classification.
Confidence: urgent assessment and hospital management are well established. Which closure, drainage or surgical approach is best depends on the actual injury and the available specialist team. The reviewed guidance and provider explanations do not establish an independently verified universal best device or supplement. Severe chest/upper-abdominal pain, breathing difficulty or swallowing difficulty after vomiting or a procedure requires emergency assessment.
- Perforation crosses the oesophageal wall. A Mallory–Weiss tear affects the lining; these names are not interchangeable.
- Tell emergency clinicians about recent vomiting, swallowing an object, an injury or an oesophageal procedure. Absence of blood or one expected symptom does not rule out serious injury.
- CT and selected contrast studies answer different questions from a routine swallowing test. Tests must be chosen for suspected leakage and the patient’s condition.
- Treatment may combine antibiotics, fluid/breathing support, controlled nutrition, drainage and endoscopic or surgical repair.
- Selected conservative care means specialist hospital surveillance with escalation available. A diet, oral supplement or home observation cannot substitute for it.
Table of contents
- Evidence summary
- Perforation, Boerhaave syndrome and lining tears
- How contamination, pressure and procedure injury arise
- Emergency imaging and hospital treatment roles
- Supported nutrition and why supplements cannot repair a leak
- Conservative care and the limits of device-success claims
- Symptoms requiring emergency assessment
- Medicines, procedure records and imaging disclosures
- Who needs specialist assessment and careful consent
- Recovery decisions and questions for the treating team
- Animal closure studies and what human proof would require
- Funding and source roles
- Frequently asked questions
- Sources and funding notes
Evidence summary
Clinical guidance, human outcome research and funding independence answer different questions. The guidance below explains care; it does not independently reproduce the trials behind a medicine or supplement.
| Claim / intervention | Evidence reviewed | Funding / conflicts | Interpretation / limits |
|---|---|---|---|
| Emergency assessment | 2025 provider explanation; 2026 NHS warnings | Mixed provider funds; national public education does not clear underlying trials. | Established emergency role; a symptom checklist cannot rule out full-wall injury. |
| Imaging, drainage and repair | WSES 2019; ESGE 2020 | WSES paper no project funding; society corporate-fee route. ESGE authors disclose device interests. | Dated consensus explains clinician roles. Commercial comparative efficacy D/excluded; no universal device ranking. |
| Non-operative management | Historical 2011 review; WSES | Review project finance unclassified; declared no conflicts does not clear all studies. | Selected specialist monitoring and escalation, not a home observation plan. |
| Nutrition and oral products | Provider intake context; NCCIH safety | Provider-specific mixed income; federal institutional context, product trials unclassified. | Supported nutrition is distinct from swallowing a claimed repair supplement. No independent perforation cure established. |
Perforation, Boerhaave syndrome and lining tears
The oesophagus passes through the neck and chest into the abdomen. A breach through its wall can therefore contaminate different spaces. The location and extent of leakage matter as much as the word “tear”. Clinicians need to know which tissues are affected, whether material is contained and whether surrounding tissue is healthy enough for repair. Original WSES classification.
Boerhaave syndrome describes a pressure-related full-wall rupture, often following forceful vomiting. Mallory–Weiss syndrome describes a split in the inner lining near the stomach junction and is principally a bleeding problem. A bleeding history cannot establish which injury is present; they need appropriate assessment rather than a home comparison of symptom lists. Cleveland Clinic: mucosal injury.
How contamination, pressure and procedure injury arise
Digestive contents belong inside the food pipe. Leakage exposes surrounding tissues to material that can cause inflammation and infection. In the chest, clinicians may refer to mediastinal or pleural contamination. A serious infection response can then develop; sepsis is a dangerous response to infection, not simply a synonym for bacteria detected in blood. Cleveland Clinic: leakage; NHS: sepsis.
Iatrogenic means associated with a medical intervention. For example, dilation stretches a narrowed oesophagus, whereas POEM intentionally cuts selected muscle fibres to treat achalasia. Perforation is a recognized complication of these procedures, distinct from their planned therapeutic action. Knowing what was actually done helps the emergency team interpret subsequent symptoms. It does not establish negligence or make every expected postoperative discomfort a perforation. Guy’s/St Thomas’: dilation; Guy’s/St Thomas’: POEM.
Emergency imaging and hospital treatment roles
Clinical assessment considers the event, examination and investigations together. CT can show the site of disruption, air or fluid outside the oesophagus and surrounding contamination. Selected contrast examinations or endoscopy may add information, but suspected leakage is not evaluated by applying an ordinary outpatient swallowing-test schedule. The team balances what a test can reveal against the patient’s condition and the risk of further injury. WSES: imaging assessment; Cleveland Clinic: contrast-test context.
The treatment has several targets: support circulation and breathing, control infection, limit leakage, manage contaminated collections and provide nutrition. This can involve intravenous medicines and fluids, drainage and a procedure to address the defect. A successful closure alone does not answer every question about infection outside the tube. The treating team assesses those issues together. Cleveland Clinic: treatment components.
Endoscopic tools include clips for closure, covered stents to divert contents across a defect and specialist vacuum approaches. Surgery may provide repair and drainage or address badly damaged tissue. ESGE’s dated iatrogenic statement limits management by the injury and available expertise. It is not a rule that every rupture must receive the same device or that endoscopy always replaces surgery. ESGE: scope and techniques.
Supported nutrition and why supplements cannot repair a leak
Avoiding further leakage can mean that the hospital team temporarily restricts swallowing and provides nutrition through an appropriate enteral or intravenous route. The route and resumption of eating are clinical decisions, not a universal number of fasting days. Someone reading that nutritional support helps recovery should not reinterpret it as permission to drink a supplement through an injured oesophagus. WSES: monitored nutritional support.
After an uncomplicated swallowing procedure, a service may check imaging and then advise when eating can resume. Those instructions have a particular clinical setting. A newly diagnosed perforation, ongoing leak or additional operation changes that setting. Ask the actual team what intake is allowed and which findings they require before changing the plan. Guy’s/St Thomas’: service-led intake decisions.
This review found no independently verified human evidence that collagen, probiotics, vitamins or herbal “repair” products seal an oesophageal perforation. General tissue-repair biology is not proof of leak control. Supplements can also affect medicines or procedures, so include them in the treatment discussion. NCCIH: supplements and procedures.
Conservative care and the limits of device-success claims
The term conservative or non-operative can be misleading outside medicine. Selected patients may receive highly monitored hospital care with antibiotics, nutritional support, drainage and ready access to escalation. It does not mean leaving a perforation to heal without assessment. A historical clinical review describes how contained injury and the patient’s overall condition influence this decision; its old device menu is not treated as a current universal algorithm. Søreide/Viste: dated clinical context.
Observational device reports can mix spontaneous rupture, endoscopic injury and postoperative leaks. Patients selected for surgery can differ from those receiving a stent. Pooling their outcomes without comparable groups can create an apparent advantage that is not a causal treatment effect. The original ESGE statement itself flags such limitations. Financial conflicts add a separate reason to avoid presenting a brand or a pooled success percentage as an independent verdict. ESGE: comparative evidence limitations.
Symptoms requiring emergency assessment
Sudden severe chest, neck or upper-abdominal pain with difficulty breathing or swallowing requires emergency assessment, especially after vomiting or an intervention. Tell clinicians about the preceding event. The absence of vomiting blood is not a reliable reason to dismiss a suspected perforation. Symptoms can vary, and a checklist cannot safely rule it out. Cleveland Clinic: warning signs; Clinical review: variable presentation.
After gastroscopy, the NHS identifies vomiting blood, repeated vomiting, breathlessness and severe or worsening chest or stomach pain as emergency warnings. Fever or tar-like stool also needs prompt advice from the hospital or urgent service. Routine soreness advice must not be applied to severe or escalating symptoms. NHS: postprocedure warning signs.
Confusion, very fast breathing or blue, pale or blotchy skin can be signs of sepsis requiring immediate help. A person need not have every symptom. In the UK use 999 or A&E when emergency signs are present; elsewhere use the corresponding emergency service. Do not drive yourself to emergency care. NHS: emergency sepsis signs.
Medicines, procedure records and imaging disclosures
Bring the medicine list and relevant procedure report if available without delaying care. Include anticoagulants, antiplatelets and supplements, since the team needs to manage bleeding, clotting and intervention risks. Do not independently stop or restart medicines while attempting to diagnose the problem. Plans for an elective procedure are also not automatically the right plan for an emergency injury. NHS: anticoagulant safety; CUH: individual procedure medicine review.
For planned imaging, tell staff about pregnancy, previous tests and relevant medical concerns. A routine barium-swallow leaflet explains how contrast imaging works, but acute suspected perforation requires an appropriate clinician-selected protocol. Do not request a preferred contrast product, consume it yourself or decide that an ordinary negative swallowing assessment excludes every possible leak. Cleveland Clinic: imaging context.
Who needs specialist assessment and careful consent
People undergoing therapeutic oesophageal procedures need a clear explanation of the intended action, complications and aftercare route. CUH’s dilation leaflet distinguishes stretching a narrowing from the risk of perforation and possible subsequent surgery. It also identifies other procedure risks, such as sedation problems or aspiration. A complication’s possibility should inform consent, rather than be converted into a numerical prediction for every patient. CUH: dilation consent context.
Existing tissue damage, treatment for cancer or prior operations can alter the clinical situation. Guy’s/St Thomas’ describes extra concern about perforation during dilation/stenting in people receiving chemotherapy or radiotherapy. Its leaflet addresses that procedure, not every spontaneous rupture or every patient receiving cancer treatment. Children, traumatic injuries and suspected swallowed objects likewise require an appropriate specialist pathway. Guy’s/St Thomas’: procedure risk context.
Chest pain also has cardiac and other emergency causes. A familiar digestive history does not make new persistent pain safe, particularly with sweating, nausea, breathlessness or pain radiating to the arm, jaw or back. Emergency clinicians evaluate the competing possibilities. NHS: chest-pain differential.
Recovery decisions and questions for the treating team
Ask what was found, where the leak is, whether contamination is controlled and what would trigger a change in treatment. Clarify which team is overseeing nutrition, medicines and any drain or stent. The plan should state how healing will be assessed and who to contact for worsening symptoms; a device being in place is not by itself a discharge criterion.
Results and follow-up arrangements matter. After a gastroscopy, tissue-sample results may come later than the immediate findings, and a further appointment may be needed. A perforation can add separate imaging and surgical follow-up. Ask which results are still pending so that the original reason for an intervention is not lost amid treatment of its complication. NHS: results and follow-up context.
If sepsis occurred, recovery may involve fatigue, physical problems and emotional or cognitive effects. The treating team can arrange support appropriate to the actual difficulties. A generic expectation of returning immediately to normal activity should not replace review of recovery after a serious infection. NHS: recovery context.
Animal closure studies and what human proof would require
Laboratory or animal work may help develop a closure technique, but cannot establish safe human repair, survival or freedom from recurrent leakage. Relevant evidence needs the injury type, patient selection, comparator, additional drainage or surgery, follow-up and funding clearly described. This article uses no animal or in-vitro finding to recommend a device or oral product. Older evidence that mixes different injuries is described as context, with no inference that a pooled result proves the best approach for an individual.
Funding and source roles
Research funding at a glance
27 disclosure entries. The counts below summarize independence tiers explicitly assigned in this article. They count disclosures, not studies, funding amounts or evidence quality.
Consult this article’s source and funding notes for named funders, countries, relationships and exceptions where available. Institutional backing, researcher interests and trial sponsorship are separate questions. Public funding alone does not establish independence; commercial ties alone do not prove a claim false. This overview is not a new financial audit.
The finance screen keeps institutional revenue, project declarations and individual interests separate. WSES’s paper reports no project funding or conflicts; its own constitution nevertheless describes corporate-alliance fees. The ESGE statement declares device-company ties, and the society has commercial revenue routes. Providers have their own care/research/donor income, rather than national NHS financing alone. These sources explain clinical roles with stated limits. Commercial comparative efficacy is D/excluded from the independent verdict; an unknown financial chain is not upgraded to independent because an author works at a university.
| Source | Funding / backers | Country / jurisdiction | Independence | Credibility / incentives / gaps |
|---|---|---|---|---|
| Cleveland Clinic: oesophageal perforation | Audited 2025 accounts: care/payers, advisory services, research grants, donors, investments; advertising. Page allocations unknown. | United States; Cleveland Clinic Foundation, Cleveland, Ohio; international care affiliates. | Tier 2 provider context, provisional; service, research, donor and commercial interests. | C, provisional — 11 September 2025; expert review/accountability support context. Page author/trial finance, simplification and provider incentives are unresolved. |
| Cleveland Clinic: July 2026 Mallory–Weiss original | Audited 2025 accounts: patient/payer care, advisory services, grants, donors and investments; advertising. Individual article and trial allocations unknown. | United States; Cleveland Clinic, Cleveland, Ohio; international provider affiliates. | Tier 2 provider context, provisional. | C, provisional — actually reviewed 16 July 2026; medical review supports context. Service/commercial incentives, complete reviewer interests and underlying trial finances unresolved. |
| WSES: original 2019 oesophageal-emergency guideline | Original 2019 paper reports no project funding and no declared conflicts. WSES constitution separately names fee-paying corporate alliance and individual members. Full ledger, wider investigator finances and supporting studies unclosed. | International authors; corresponding French hospital affiliation; society HQ Bologna, Italy. | Tier 2 dated clinical consensus, provisional; source-study finance unclassified. | C, provisional — full original clinical and finance declarations read. Emergency-care accountability and explicit methods favor context; mostly low-level evidence, 2019 age and incomplete financial chain limit comparative efficacy. |
| WSES: original constitution and financial routes | Individual membership and corporate-alliance fees explicitly described; treasurer required to present audited accounts. Current audited ledger, company list and allocations not found. | Italy; own constitution and current footer give Via Cracovia 23, Bologna. | Tier 3 society financial/governance self-disclosure. | C, provisional — original clauses and jurisdiction checked; document has no stated current reporting year and is not proof that audits were completed or public. |
| Søreide and Viste: original 2011 clinical review | Original declares no competing interests; no dedicated funding statement located. Institutional affiliations listed, but complete hospital, author and cited-study finances not traced. | Norway; Stavanger University Hospital, Haukeland University Hospital and University of Bergen. | Unclassified project finance; Tier 2 historical clinical-review context, provisional. | C, provisional — actual full relevant text/declaration read, dated 30 October 2011. Clinical experience supports anatomy/work-up context, but old imaging/device menus and non-randomised comparisons are limits. |
| ESGE: original 2020 iatrogenic-perforation statement | Society-led statement; full original interests list Boston Scientific consulting/research, Olympus departmental grant/equipment, Medtronic/Cook lectures, Cook/Abbott departmental research. Own strategic finance plan: corporate grants/sponsorship, membership, congress and endorsement income. No current audited allocation located. | International authors; ESGE Munich, Germany. | Tier 2 dated clinical consensus, provisional; commercial comparative efficacy D/excluded. | C, provisional — relevant original sections and all author interests read; published 11 August 2020. Explicit resource/expertise limits favor context, but project allocation and supporting studies not cleared. |
| ESGE: original strategic finance plan | Membership, corporate education grants/sponsorship, congress registrations, endorsement fees and commercial activities explicitly described. | Germany; ESGE e.V., Munich. | Tier 3 society financial self-disclosure; material commercial routes. | C, provisional — original nine-page plan read. Not a dated audited 2025–2026 ledger; figure percentages not presented as current accounts or assigned to this guideline. |
| ESGE: current individual membership terms | Society charges membership fees; original terms read. | Germany; Munich, international members. | Tier 3 own revenue-route disclosure. | B, provisional for stated fees/process — not independently audited receipts and no named trial clearance. |
| ESGE: original office record | Society address record; revenue routes described separately. | Germany; Landwehrstraße 9, Munich. | Tier 3 own jurisdiction record. | B, provisional — original address read; jurisdiction establishes accountability context rather than clinical benefit. |
| Guy’s and St Thomas’: Dilation or stent overview | Own 2025–2026 accounts: NHS/private care, commercial research and charity income; leaflet-specific funding and underlying device/medicine trials unresolved. | United Kingdom; London NHS Foundation Trust. | Tier 2 provider, provisional; mixed care/private/research interests. | C, provisional — November 2023, due November 2026; local clinical accountability supports context. Service interests, page allocations and trial finance remain gaps. |
| Guy’s and St Thomas’: After dilation or a stent | Own 2025–2026 accounts: NHS/private care, commercial research and charity income; leaflet-specific funding and underlying device/medicine trials unresolved. | United Kingdom; London NHS Foundation Trust. | Tier 2 provider, provisional; mixed care/private/research interests. | B, provisional — November 2023, due November 2026; local clinical accountability supports context. Service interests, page allocations and trial finance remain gaps. |
| Guy’s and St Thomas’: POEM overview | Predominantly NHS commissioner income; own 2025/26 annual accounts also identify private-patient, research/development, charitable and commercial income. Specific page funding and expert payments not disclosed. | United Kingdom; Guy’s and St Thomas’ NHS Foundation Trust, London. | Tier 2 institution, provisional; mixed public/private and commercial income. | B, provisional — clinical care obligations and audited accounts favor accuracy; procedure-provider interests, local protocols and unknown page-specific conflicts remain. |
| Cambridge University Hospitals: gastroscopy and dilation | Own 2025–2026 accounts: NHS/private/overseas care, research, training and donations; NIHR infrastructure includes industry/charity partnerships. Individual leaflet payments and device-study finance unknown. | United Kingdom; Cambridge University Hospitals NHS Foundation Trust, Hills Road, Cambridge. | Tier 2 provider context, provisional; mixed clinical/commercial-research interests. | C, provisional — approved 3 October 2024; identifiable endoscopy service. Blanket no-real-alternatives, universal eating and single pooled complication-risk statements are not adopted. |
| Guy’s/St Thomas’: audited 2025–26 accounts | Guy’s and St Thomas’ NHS Foundation Trust; actual audited 2025–2026 accounts reports NHS commissioner funding, private patient income, research/education, charitable grants and commercial activities. Its commercial-partnership section names Johnson & Johnson Managed Services, Diaverum and Active Care Group; these are institutional ties, not demonstrated funding of this leaflet. Complete leaflet allocation, author interests and underlying procedure studies remain unclosed. | United Kingdom; NHS foundation trust and hospitals in London, England, with Harefield site. | Tier 3 institutional financial self-report. | B, provisional — statutory financial original read; own institutional reporting and no page-level attribution are limits. |
| Cambridge University Hospitals: audited 2025–26 accounts | Cambridge University Hospitals NHS Foundation Trust: actual 2025–2026 accounts documents NHS commissioners, private patients, research/training, donations and other services. NIHR infrastructure and industry/charity research partnerships are disclosed; no attribution to this page or complete contributor/trial financial chain established. | United Kingdom; Addenbrooke’s and The Rosie, Hills Road, Cambridge, England; actual original contact checked. | Tier 3 institutional financial self-report. | B, provisional — statutory financial report actually read; own reporting and no page allocation are limits. |
| Cleveland Clinic: barium swallow original | Audited 2025 accounts: care/payers, advisory services, research grants, donors, investments; advertising. Page allocations unknown. | United States; Cleveland Clinic Foundation, Cleveland, Ohio; international care affiliates. | Tier 2 provider context, provisional; service, research, donor and commercial interests. | C, provisional — 12 December 2025; expert review/accountability support context. Page author/trial finance, simplification and provider incentives are unresolved. |
| Cleveland Clinic: original audited 2025/2024 accounts | Provider statutory report; externally audited by EY. Patient/payer revenue, advisory services, research grants, corporate/foundation/individual pledges and investments. | United States; Cleveland Clinic Health System, Cleveland, Ohio. | Tier 3 provider financial self-report with external audit. | B, provisional — issued 9 March 2026, complete 75-page original accessed and relevant notes read. Audit concerns the accounts, not this article or intervention trials. |
| Cleveland Clinic: advertising policy | Site accepts advertising/sponsor revenue; provider retains content/placement approval and states editorial separation. | United States; Cleveland, Ohio. | Tier 3 own commercial-policy disclosure. | B, provisional — policy itself read; January 2020 guidelines state they can change. Actual page advertiser amounts and compliance not independently audited. |
| Cleveland Clinic: editorial policy | Institutional writing and expert-review process; mixed provider funds above, no individual reviewer-payment ledger. | United States; Cleveland, Ohio. | Tier 3 own process disclosure. | B, provisional — actual policy describes professional writers and medical-expert review. Accuracy incentive is credible; an institutional perspective and unverified individual conflicts remain. |
| NHS: August 2026 gastroscopy original | National NHS accounts. Individual page/expert payments not supplied; provider trust finances are separate. | United Kingdom; national NHS England patient education. | Tier 1 institutional education, provisional. | B, provisional — actual 13 August 2026 text, next review 13 August 2029. Care accountability supports investigation/aftercare context; individual expert and intervention-trial funding remains unknown. |
| NHS: vomiting blood | UK public health service; statutory annual accounts provenance. Page-specific sponsor/expert payments not disclosed; individual-provider and research income can differ. | United Kingdom; NHS England national patient information. | Tier 1 institutional education, provisional; complete page financing unknown. | B, provisional — care accountability and clear triage guidance; simplified advice, 18 August 2025; due August 2028; not a trial-level financial audit. |
| NHS: anticoagulant adverse effects | UK public health service; statutory annual accounts provenance. Page-specific sponsor/expert payments not disclosed; individual-provider and research income can differ. | United Kingdom; NHS England national patient information. | Tier 1 institutional education, provisional; complete page financing unknown. | B, provisional — care accountability and clear triage guidance; simplified advice, Current accessed page; not a trial-level financial audit. |
| NCCIH: supplements and medicine safety | NIH federal agency; NCCIH budget information. Page-level commercial sponsor not named; underlying review/trial funding not exhaustively traced. | United States; NCCIH, Bethesda, Maryland; federal education. | Tier 1 institution; underlying trials unclassified. | B, provisional — public review and explicit uncertainty favor accuracy; an older synthesis does not certify any product or remove trial sponsorship. |
| NHS England: national 2024–2025 accounts | Statutory national public-health accounts; hospital trusts have separate private/research/charitable income. | United Kingdom; national NHS England. | Tier 3 national financial self-report context. | B, provisional — dated public accountability; does not establish provider, page-author or trial independence. |
| NCCIH: federal budget | NIH federal agency; NCCIH budget information. Page-level commercial sponsor not named; underlying review/trial funding not exhaustively traced. | United States; NCCIH, Bethesda, Maryland; federal education. | Tier 1 institution; underlying trials unclassified. | B, provisional — public review and explicit uncertainty favor accuracy; an older synthesis does not certify any product or remove trial sponsorship. |
| NHS: May 2026 sepsis original | National NHS accounts. Individual page/expert and underlying trial payments not supplied; individual trusts have separate accounts. | United Kingdom; national NHS England health education. | Tier 1 institutional context, provisional. | B, provisional — actually reviewed 14 May 2026, next review May 2029. Explicit age-specific triage and care accountability support safety; simplification and unclassified page/trial finance remain. |
| NHS: chest-pain triage original | National NHS accounts. Individual page/expert and underlying trial payments not supplied; individual trusts have separate accounts. | United Kingdom; national NHS England health education. | Tier 1 institutional context, provisional. | C, provisional — last reviewed 8 August 2023, next review August 2026 now passed. Care accountability supports warning context corroborated with current gastroscopy/perforation sources. |
Frequently asked questions
Does Boerhaave syndrome mean every oesophageal perforation?
No. It names a pressure-associated form, often after vomiting. Procedure injury, trauma and other causes belong to the broader perforation category. WSES: categories.
Can a perforation be treated without an operation?
Selected cases may receive specialist monitored non-operative care. This remains active hospital treatment, with escalation according to the injury and clinical course. Clinical review: selection context.
Can food or collagen seal the hole?
No independently verified human product benefit was established here. Intake and supported nutrition must follow the treating team’s plan. NCCIH: supplement safety.
Is chest pain after vomiting always perforation?
No, but severe or persistent pain and breathing problems need emergency assessment. Cardiac and other serious causes also require consideration. NHS: chest pain.
Sources and funding notes
Actual clinical originals and date-specific financial disclosures checked. WSES and Søreide/Viste publisher originals and the ESGE full statement were accessed; no project funding is not identical to no society or individual commercial ties. The August 2023 NHS chest-pain page has a passed review date, disclosed as C and used alongside current warning sources. No pooled mortality, fixed delay allowance, personal antibiotics, medication withdrawal, tube manipulation, fasting or home repair regimen is provided.
- Cleveland Clinic: oesophageal perforation — Actually reviewed 11 September 2025: full-wall hole, contamination and emergency context; pooled prevalence, mortality and waiting/healing deadlines excluded.
- Cleveland Clinic: July 2026 Mallory–Weiss original — Actually reviewed 16 July 2026: mucosal Mallory–Weiss injury distinguished; no inference that bloody vomiting excludes full-wall damage.
- WSES: original 2019 oesophageal-emergency guideline — Contained versus uncontained injury, CT, specialist surveillance and repair roles; old pooled mortality/device-comparison percentages not adopted.
- WSES: original constitution and financial routes — Corporate support route is separate from the paper’s no-project-funding declaration; a .org.uk domain is not proof of UK headquarters.
- Søreide and Viste: original 2011 clinical review — Nonspecific presentation and limitations of patient-series comparisons; no contemporary trial-free claim, no old imaging sequence or numeric prognosis adopted.
- ESGE: original 2020 iatrogenic-perforation statement — Iatrogenic symptoms/CT, closure/monitoring and technical terminology. No pooled clip/stent/vacuum success or universal device superiority.
- ESGE: original strategic finance plan — Documented revenue routes and current audit/allocation gap.
- ESGE: current individual membership terms — Confirms fee route without assuming it is the society’s sole income.
- ESGE: original office record — Headquarters/jurisdiction only.
- Guy’s and St Thomas’: Dilation or stent overview — Actually November 2023, review due November 2026: dilation/stent purpose and perforation-consent context, not a repair-success comparison.
- Guy’s and St Thomas’: After dilation or a stent — Actually November 2023: service-led postprocedure monitoring and oral-intake decisions; its routine discharge/drink timetable is not applied to perforation.
- Guy’s and St Thomas’: POEM overview — Actually March 2025, next review March 2028: planned muscle cutting for achalasia versus perforation as complication; no numerical efficacy or reflux estimate adopted.
- Cambridge University Hospitals: gastroscopy and dilation — Actually approved 3 October 2024: dilation, individual medicine review and perforation risk; no pooled risks, insulin chart or personal fasting/withdrawal copied.
- Guy’s/St Thomas’: audited 2025–26 accounts — Provider financial channels and institutional relationships; no clinical efficacy.
- Cambridge University Hospitals: audited 2025–26 accounts — Actual provider financial routes, research and institutional partnership context.
- Cleveland Clinic: barium swallow original — Actually 12 December 2025: contrast imaging context, pregnancy and prior-image disclosure; routine swallow study not interchangeable with acute perforation CT.
- Cleveland Clinic: original audited 2025/2024 accounts — Printed pp9–12, 18–20, 22 and 32 identify routes; no claim of complete June 2026 interim or page-specific independence.
- Cleveland Clinic: advertising policy — Ad-finance route and stated editorial safeguards, not disease efficacy.
- Cleveland Clinic: editorial policy — Process context; not a guarantee that every clinical sentence is accurate or financially independent.
- NHS: August 2026 gastroscopy original — Actually 13 August 2026: emergency postprocedure warning signs and results follow-up; routine outpatient discharge/fasting timetable excluded.
- NHS: vomiting blood — Urgent/emergency bleeding distinction; local emergency number replaces UK-specific instructions.
- NHS: anticoagulant adverse effects — Actually 9 September 2024: bleeding and clotting medicine disclosure; no individual stop/restart plan.
- NCCIH: supplements and medicine safety — Supplement and procedure interaction disclosure; no independently verified human perforation-healing benefit established.
- NHS England: national 2024–2025 accounts — National patient-information provenance only.
- NCCIH: federal budget — Public institutional education funding, separate from product and trial finance.
- NHS: May 2026 sepsis original — Serious infection-response, emergency warning and hospital treatment/recovery context; sepsis is not defined as bloodstream bacteria alone.
- NHS: chest-pain triage original — Chest-pain emergency differential; no reassurance from a digestive history, and no individual heart-attack diagnosis.
Educational information reviewed 4 October 2026. This guide supports an informed clinical discussion; it does not diagnose an individual or provide a personal treatment regimen.
Have a question — or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.
One daily research roundup
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.